MECOM and ovarian carcinoma: In totality, our results thus present a new epigenetic based therapeutic opportunity to target ovarian cancer cells harboring MECOM amplification and may also suggest potential of combining JIB-04 epidrug as neo-adjuvant with standard platin based chemotherapy.